Clinical Significance of Homologous Recombination Deficiency Score Testing In Endometrial Cancer

<p><strong>Objectives: </strong>Homologous recombination deficiency (HRD) score is related to chemotherapy response in breast and ovarian cancers. The role of HRD is unknown in endometrial cancer. We examined the relationship between HRD score and survival in a cohort of endometrial cancer patients and with tumor growth using murine orthotopic models.</p> <p><strong>Methods: </strong>TCGA was queried to determine frequency and clinical significance of alterations in the HR pathway in endometrial cancer. 137 formalin-fixed paraffin-embedded endometrioid adenocarcinoma patient samples were tested for HRD score, microsatellite instability (MSI) and high mutation load (HML) using a next generation sequencing assay targeting the coding regions of 43 genes and 54,091 genome wide single nucleotide polymorphisms (SNPs) developed by Myriad Genetics. The HRD score is the sum of three previously described scores (loss of heterozygosity, telomeric allelic imbalance, and large-scale state transition) that quantitate genome rearrangement. Clinical records were obtained. HRD scores were also generated on a panel of established endometrial cancer cell lines and their in vivo growth and response to olaparib and chemotherapy were assessed. Tumor growth and patterns of metastatic spread were assessed in orthotopic mouse models of endometrial cancer.</p> <p><strong>Results: </strong>Median age at diagnosis was 62 years. The majority of patients presented with early stage disease (54%, 11%, 27%, 8% stage I, II, III, IV respectively), and FIGO grade 2 histology (1%, 73%, 26% grade 1, 2, 3). HRD scores were generated for 112 patient samples, MSI status was determined for 126 samples, and HML status determined for 137 samples. The median HRD score was 3. Patients with HRD score ≥ 10 trended toward worse survival as compared to patients with HRD score <10 >(P=0.17). Hec1a cell line (HRD score = 19) was highly sensitive to olaparib and was selected for <em>in vivo</em> use. At the time of necropsy, mice injected with Hec1a and treated with PARP inhibitor had significantly decreased tumor growth and HR function as compared with untreated controls, regardless of BRCA1 function.</p> <p><strong>Conclusions: </strong>High HRD score was associated with worse survival in our patient cohort. Our findings support the use of HRD score in guiding the choice of adjuvant therapy for patients with advanced endometrial cancer.</p>

Name thesis:degree_name

Masters of Science (MS)

Level thesis:degree_level

Thesis (MS)

Year dc:date.available

2016

Author dc:creator

• Hansen, Jean M

Contributors dc:contributor

• Anil K. Sood
• Keith Baggerly
• Menashe Bar-Eli

• Medicine and Health Sciences
• Translational Medical Research

Repository record dc:identifier

https://digitalcommons.library.tmc.edu/utgsbs_dissertations/683

OAI identifier oai:identifier

oai:digitalcommons.library.tmc.edu:utgsbs_dissertations-1727